{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:03:55Z","timestamp":1787828635023,"version":"build-2784847793"},"reference-count":136,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In evidence\u2010based guidelines published in 2000, topiramate was a third\u2010tier migraine preventive with no scientific evidence of efficacy; recommendation for its use reflected consensus opinion and clinical experience. Its neurostabilizing activity, coupled with its favorable weight profile, made topiramate an attractive alternative to other migraine preventives that caused weight gain. When guidelines for migraine prevention in episodic migraine were published in 2012, topiramate was included as a first\u2010line option based on double\u2010blind, randomized controlled trials involving nearly 3000 patients. The scientific and clinical interest in topiramate has generated a large body of data from randomized controlled trials, meta\u2010analyses, patient registries, cohort studies, and claims data analyses that have more fully characterized its role as a migraine preventive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This article will review the profile of topiramate that has emerged out of the past decade of research and clinical use in migraine prophylaxis. It will also address the rationale for extended\u2010release (XR) formulations in optimizing topiramate therapy in migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>\n                      Topiramate has activity at multiple molecular targets, which may account for why it is effective in migraine and most other, more specific, anticonvulsants are not. Based on randomized controlled trials, topiramate reduces migraine frequency and acute medication use, improves quality of life, and reduces disability in patients with episodic migraine and in those with chronic migraine with or without medication overuse headache. Its efficacy in chronic migraine is not improved by the addition of propranolol. Topiramate's ability to prevent progression from high\u2010frequency episodic migraine to chronic migraine remains unclear. Consistent with clinicians\u2019 perceptions, migraineurs are more sensitive to topiramate\u2010associated side effects than patients with epilepsy. Paresthesia is a common occurrence early in treatment but is rarely cause for terminating topiramate treatment. Cognitive problems occur much less frequently than paresthesia but are more troublesome in terms of treatment discontinuation. Cognitive complaints can often be managed by slowly increasing the topiramate dose in small increments to allow habituation. As with other carbonic anhydrase inhibitors, topiramate has metabolic effects that favor the development of metabolic acidosis and possibly renal stones. Because migraineurs have an increased risk of renal stones independent of topiramate exposure, clinicians should counsel all migraine patients to maintain hydration. Abrupt onset of blurring, other visual disturbances, and\/or ocular pain following topiramate's initiation should be evaluated promptly since this may indicate rare but potentially sight\u2010threatening idiosyncratic events. Postmarketing evidence has shown that first\u2010trimester exposure to topiramate monotherapy is associated with increased occurrence of cleft lip with or without cleft palate (Pregnancy Category D). Even though topiramate's long half\u2010life would seemingly support q.d. dosing, randomized controlled migraine trials used b.i.d. administration of immediate\u2010release (IR) topiramate, which has more favorable plasma concentration\u2010time profile (ie, lower peak concentrations and higher trough concentrations) than q.d. IR dosing. Given the sensitivity of migraineurs to topiramate\u2010related adverse events, particularly cognitive effects, pharmacokinetic profiles should be considered when optimizing migraine outcomes. The extended\u2010release (XR) formulations Qudexy\n                      <jats:sup>\u00ae<\/jats:sup>\n                      XR (Upsher\u2010Smith Laboratories) and Trokendi XR\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (Supernus Pharmaceuticals) were specifically designed to achieve the adherence benefits of q.d. dosing but with more favorable (ie, more constant) steady\u2010state plasma concentrations over the 24\u2010hour dosing interval vs IR topiramate b.i.d. Intriguing results from a study in healthy volunteers showed consistently less impairment in neuropsychometric tests of verbal fluency and mental processing speed with an XR topiramate formulation (Trokendi XR) vs IR topiramate b.i.d. These findings suggest a pharmacodynamic effect associated with significantly reducing plasma concentration fluctuation when topiramate absorption is slowed. Results of retrospective studies in migraineurs treated with XR topiramate appear to support a clinically meaningful benefit of XR topiramate vs IR topiramate in terms of significantly fewer cognitive effects, improved adherence, and overall better outcomes of migraine prophylaxis with topiramate.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.12997","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T14:38:12Z","timestamp":1480516692000},"page":"165-178","source":"Crossref","is-referenced-by-count":111,"title":["Topiramate in Migraine Prevention: A 2016 Perspective"],"prefix":"10.1111","volume":"57","author":[{"given":"Stephen D.","family":"Silberstein","sequence":"first","affiliation":[{"name":"Jefferson Headache Center Thomas Jefferson University, Philadelphia  PA 19107 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12034"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01323.x"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01369.x"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12755"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.20.2640"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.6.754"},{"key":"e_1_2_14_8_1","author":"Gray RN","journal-title":"Drug Treatments for the Prevention of Migraine Headache"},{"key":"e_1_2_14_9_1","first-page":"S1","article-title":"Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis","volume":"39","author":"Pringsheim T","year":"2012","journal-title":"Can J Neurol Sci."},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02163.x"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2008.00041.x"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.4501006.x"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)00543-0"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702096"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)38047-4"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02170.x"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02166.x"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2004.04.040"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01001.x"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02173.x"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0040032"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705617"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2005.35304.x"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00171-X"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02164.x"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02171.x"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-18-07069.2003"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(03)00120-7"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:NERE.0000010456.92887.3b"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.02186.x"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03259.x"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.153908"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00045-4"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02167.x"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02165.x"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.12.006"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10000"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2005.03.045"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90373-5"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(96)00492-4"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2005.08.015"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.2.627"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.3.473"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.18800.x"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02169.x"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2005.01.001"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.12.010"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2011.05.009"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00205"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2014.885835"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00767.x"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706290"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411418259"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102412472069"},{"key":"e_1_2_14_56_1","first-page":"S99","article-title":"A preliminary analysis of GRIK4 genotype and outcomes of topiramate treatment in high frequency episodic migraine","volume":"11","author":"Chu M","year":"2010","journal-title":"J Headache Pain."},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00538.x"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-4-12"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01858.x"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnr.0000175250.33159.a9"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20778"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2008.07.014"},{"key":"e_1_2_14_63_1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1468-2982.2009.02021.x","article-title":"Cortical spreading depression\u2010associated cerebral blood flow changes induced by mechanical stimulation are modulated by AMPA and GABA receptors","volume":"30","author":"Holland PR","year":"2010","journal-title":"Cephalalgia."},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413515344"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.490"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.8.965"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-0464-6"},{"key":"e_1_2_14_68_1","first-page":"251","article-title":"Analysis of pooled data from two pivotal controlled trials on the efficacy of topiramate in the prevention of migraine","volume":"107","author":"Freitag FG","year":"2007","journal-title":"J Am Osteopath Assoc."},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2005.00612.x"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05183.x"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-56"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.03.020"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00684.x"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00950.x"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01508.x"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01326.x"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01859.x"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31824d5846"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00648.x"},{"key":"e_1_2_14_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410372427"},{"key":"e_1_2_14_81_1","first-page":"A147","article-title":"Topiramate for migraine prevention in adolescent patients","volume":"62","author":"Winner P","year":"2004","journal-title":"Neurology."},{"key":"e_1_2_14_82_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-0642"},{"key":"e_1_2_14_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12105"},{"key":"e_1_2_14_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70272-7"},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-007-0351-x"},{"key":"e_1_2_14_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00754.x"},{"key":"e_1_2_14_87_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060590"},{"key":"e_1_2_14_88_1","doi-asserted-by":"publisher","DOI":"10.2165\/11314380-000000000-00000"},{"key":"e_1_2_14_89_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802664199"},{"key":"e_1_2_14_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.12.010"},{"key":"e_1_2_14_91_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414547138"},{"key":"e_1_2_14_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.203"},{"key":"e_1_2_14_93_1","first-page":"1","article-title":"Topiramate\u2010induced paresthesia is more frequently reported by migraine than epileptic patients","author":"Sedighi B","year":"2016","journal-title":"Neurological Sci."},{"key":"e_1_2_14_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2007.00389.x"},{"key":"e_1_2_14_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.01869.x"},{"key":"e_1_2_14_96_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02020.x"},{"key":"e_1_2_14_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.01.042"},{"key":"e_1_2_14_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.06.048"},{"key":"e_1_2_14_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12751"},{"key":"e_1_2_14_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2015.03.009"},{"key":"e_1_2_14_101_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414553825"},{"key":"e_1_2_14_102_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S27695"},{"key":"e_1_2_14_103_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411410083"},{"key":"e_1_2_14_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02114.x"},{"key":"e_1_2_14_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01853.x"},{"key":"e_1_2_14_106_1","unstructured":"Food & Drug Administration. FDA drug safety communication: Risk of oral clefts in children born to mothers taking Topamax (topiramate).http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm245085htm.2011. Accessed February 3 2016."},{"key":"e_1_2_14_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2015.03.003"},{"key":"e_1_2_14_108_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39559.675891.AD"},{"key":"e_1_2_14_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12165"},{"key":"e_1_2_14_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.4501007.x"},{"key":"e_1_2_14_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.08.029"},{"key":"e_1_2_14_112_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1998.1801052.x"},{"key":"e_1_2_14_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.11.029"},{"key":"e_1_2_14_114_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0268-5"},{"key":"e_1_2_14_115_1","unstructured":"Upsher\u2010Smith Laboratories Inc. Qudexy\u00aeXR prescribing information. Maple Grove MN. Rev. 0315. Accessed February 3 2016 at:http:\/\/www.upsher-smith.com\/wp-content\/uploads\/QXR-MktgInsert.pdf."},{"key":"e_1_2_14_116_1","unstructured":"Supernus Pharmaceuticals Inc. Trokendi XR\u00aeprescribing information. Rockville MD. Rev. May 2015. Accessed February 3 2016 at:http:\/\/www.trokendixr.com\/assets\/sites\/2\/2015\/09\/TrokendiXR-PI-Standard-Letter-FINAL-09-2015.pdf."},{"key":"e_1_2_14_117_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12225"},{"key":"e_1_2_14_118_1","first-page":"245","article-title":"Steady\u2010state bioequivalence of extended\u2010release once\u2010daily SPN\u2010538 (Trokendi XR\u2122) to immediate\u2010release topiramate (TPM\u2010IR, Topamax\u00ae)","volume":"82","author":"Johnson J","year":"2014","journal-title":"Neurology."},{"key":"e_1_2_14_119_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02598.x"},{"key":"e_1_2_14_120_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102412444015"},{"key":"e_1_2_14_121_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318206ca02"},{"key":"e_1_2_14_122_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.2.321"},{"key":"e_1_2_14_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00322.x"},{"key":"e_1_2_14_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2004.06.017"},{"key":"e_1_2_14_125_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1684\/j.1950-6945.2005.tb00128.x","article-title":"Topiramate: A prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy","volume":"7","author":"Froscher W","year":"2005","journal-title":"Epileptic Disord."},{"key":"e_1_2_14_126_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03322.x"},{"key":"e_1_2_14_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2012.04.120"},{"key":"e_1_2_14_128_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12556"},{"key":"e_1_2_14_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.646"},{"key":"e_1_2_14_130_1","first-page":"S43","article-title":"Cognitive effects of extended\u2010release once\u2010daily SPN\u2010538 (Trokendi XR\u2122) vs bid immediate\u2010release topiramate (TPM\u2010IR, Topamax\u00ae) in healthy volunteers","volume":"82","author":"Johnson J","year":"2014","journal-title":"Neurology."},{"key":"e_1_2_14_131_1","article-title":"Population pharmacokinetic modeling of immediate-and extended-release topiramate (SPN\u2010538, Trokendi XR) in adults with epilepsy: Characterization of different absorption rates","volume":"15","author":"SE Roers","year":"2015","journal-title":"Epilepsy Curr"},{"key":"e_1_2_14_132_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1212\/WNL.84.14_supplement.P3.190","article-title":"Topiramate (TPM) input rate and impaired verbal fluency: Observations with different formulations","volume":"84","author":"Marino S","year":"2015","journal-title":"Neurology."},{"key":"e_1_2_14_133_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200110000-00006"},{"key":"e_1_2_14_134_1","first-page":"256","article-title":"Pragmatic assessment of Trokendi XR\u00ae (extended\u2010release topiramate) use in clinical practice","volume":"78","author":"O'Neal W","year":"2016","journal-title":"Neurology."},{"key":"e_1_2_14_135_1","first-page":"PF59","article-title":"Retrospective claims\u2010based comparative health outcomes study: Trokendi XR\u00ae (extended\u2010release topiramate) vs. immediate\u2010release topiramate","volume":"58","author":"O'Neal W","year":"2016","journal-title":"Headache."},{"key":"e_1_2_14_136_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00757.x"},{"key":"e_1_2_14_137_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01431.x"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhead.12997","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.12997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T07:52:36Z","timestamp":1762069956000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.12997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/head.12997"],"URL":"https:\/\/doi.org\/10.1111\/head.12997","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,30]]}}}